Search results
Barrett Business Services (NASDAQ:BBSI) shareholders have earned a 13% CAGR over the last five years
Simply Wall St. via Yahoo Finance· 6 hours agoWhile markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just ...
Investors in Ferguson (NYSE:FERG) have seen stellar returns of 227% over the past five years
Simply Wall St. via Yahoo Finance· 6 hours agoThe TSR incorporates the value of any spin-offs or discounted capital raisings, along with any...
Youdao, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Simply Wall St. via Yahoo Finance· 8 hours agoThe consensus price target is just an average of individual analyst targets, so - it could be handy...
Investors in CompuGroup Medical SE KGaA (ETR:COP) have unfortunately lost 57% over the last three...
Simply Wall St. via Yahoo Finance· 13 hours agoWhile markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just ...
Investing in Chartwell Retirement Residences (TSE:CSH.UN) a year ago would have delivered you a 47%...
Simply Wall St. via Yahoo Finance· 6 hours agoThe TSR incorporates the value of any spin-offs or discounted capital raisings, along with any...
There’s a Key Flaw in How We Think About Sickness—and the Solution Is Right in Front of Us.
Slate via Yahoo News· 6 hours agoI saw how doctors prescribing legal aid can help clear chronic health conditions and, according to...
Chin Well Holdings Berhad (KLSE:CHINWEL) shareholders have endured a 14% loss from investing in the...
Simply Wall St. via Yahoo Finance· 6 days agoDividends? As well as measuring the share price return, investors should also consider the total...
Panther Securities (LON:PNS) shareholders have earned a 1.3% CAGR over the last five years
Simply Wall St. via Yahoo Finance· 11 hours agoDividends? As well as measuring the share price return, investors should also consider the total...
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing...
KOIN News 6 Portland· 1 day agoNovartis today presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G...
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further...
WPRI Providence· 1 day agoIn the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) ...